These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8587850)

  • 21. The clinical impact of magnetic resonance imaging in diagnosing focal hepatic lesions and suspected cancer.
    Shah AJ; Parsons B; Pope I; Callaway M; Finch-Jones MD; Thomas MG
    Clin Imaging; 2009; 33(3):209-12. PubMed ID: 19411027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dilute oral iron solutions as gastrointestinal contrast agents for magnetic resonance imaging; initial clinical experience.
    Wesbey GE; Brasch RC; Goldberg HI; Engelstad BL; Moss AA
    Magn Reson Imaging; 1985; 3(1):57-64. PubMed ID: 3923293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening of colonic tumors by air-inflated magnetic resonance (MR) colonography.
    Lam WW; Leung WK; Wu JK; So NM; Sung JJ
    J Magn Reson Imaging; 2004 Apr; 19(4):447-52. PubMed ID: 15065168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
    Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
    Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paramagnetic pharmaceuticals for magnetic resonance imaging.
    Wesbey GE; Engelstad BL; Brasch RC
    Physiol Chem Phys Med NMR; 1984; 16(2):145-55. PubMed ID: 6095341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Elimination of artifacts in MRCP: technical consideration].
    Ohgi K; Satoh K; Tanaka S; Higami T; Furukawa T; Akiyama H; Kimura S; Uehara K; Murata K; Higashi M
    Nihon Rinsho; 1998 Nov; 56(11):2854-8. PubMed ID: 9847609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear magnetic resonance contrast enhancement study of the gastrointestinal tract of rats and a human volunteer using nontoxic oral iron solutions.
    Wesbey GE; Brasch RC; Engelstad BL; Moss AA; Crooks LE; Brito AC
    Radiology; 1983 Oct; 149(1):175-80. PubMed ID: 6611926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Large scale clinical evaluation of bowel contrast agent containing ferric ammonium citrate in MRI.
    Hirohashi S; Uchida H; Yoshikawa K; Fujita N; Ohtomo K; Yuasa Y; Kawamura Y; Matsui O
    Magn Reson Imaging; 1994; 12(6):837-46. PubMed ID: 7968283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of oral contrast agents for abdominal magnetic resonance imaging.
    Kraus BB; Rappaport DC; Ros PR; Torres GM
    Magn Reson Imaging; 1994; 12(6):847-58. PubMed ID: 7968284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colon carcinoma: MR imaging with CO2 enema--pilot study.
    Lomas DJ; Sood RR; Graves MJ; Miller R; Hall NR; Dixon AK
    Radiology; 2001 May; 219(2):558-62. PubMed ID: 11323488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technical note: dynamic analysis of the pharynx during swallowing using Turbo-FLASH magnetic resonance imaging combined with an oral positive contrast agent--a preliminary study.
    Suto Y; Kamba M; Kato T
    Br J Radiol; 1995 Oct; 68(814):1099-102. PubMed ID: 7496712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferric ammonium citrate-cellulose paste for opacification of the esophageal lumen on MRI.
    Ogawa Y; Noda Y; Morio K; Nishioka A; Inomata T; Yoshida S; Toki T; Ogoshi S
    J Comput Assist Tomogr; 1996; 20(3):455-9. PubMed ID: 8626911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ferrite particles as an MR contrast agent.
    Saini S; Ferrucci JT
    Radiology; 1988 Dec; 169(3):656. PubMed ID: 3186987
    [No Abstract]   [Full Text] [Related]  

  • 34. The clinical value of ferric ammonium citrate: a positive oral contrast agent for T1-weighted MR imaging of the upper abdomen.
    Malcolm PN; Brown JJ; Hahn PF; Stillman AE; Li KC; Kawamura Y; Tanaka T; Noel JK; Molony BA; Johnson MF; Hildebolt CF
    J Magn Reson Imaging; 2000 Nov; 12(5):702-7. PubMed ID: 11050639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short communication: the use of sodium ironedetate (Sytron) as an MRI rectal contrast agent.
    Buxton PJ
    Br J Radiol; 1996 Mar; 69(819):266-8. PubMed ID: 8800872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Elimination of bowel fluid artifact on abdominal DWI using oral contrast agent ferric ammonium citrate].
    Takahashi T; Kato K; Nishizawa T; Nakazawa Y
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2008 May; 64(5):573-8. PubMed ID: 18509218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enteric MRI contrast agents: comparative study of five potential agents in humans.
    Tart RP; Li KC; Storm BL; Rolfes RJ; Ang PG
    Magn Reson Imaging; 1991; 9(4):559-68. PubMed ID: 1779727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The "aura" sign: an unusual cultural variant affecting MR imaging.
    Duncan IC
    AJR Am J Roentgenol; 2001 Dec; 177(6):1487. PubMed ID: 11717119
    [No Abstract]   [Full Text] [Related]  

  • 39. Making Contrast Material Obsolete: Functional Lung Imaging with MRI.
    Wielpütz MO
    Radiology; 2020 Jul; 296(1):200-201. PubMed ID: 32347784
    [No Abstract]   [Full Text] [Related]  

  • 40. [MR imaging of colonic cancer with retrograde administration of contrast material containing ferric ammonium citrate].
    Mizuguchi M; Matsuo Y; Fukahori T; Kudo S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Dec; 55(15):1063-5. PubMed ID: 8587850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.